

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-112024-0001215

Date: 25/11/2024

# Address / Email:

Dear

# **Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

### Request

How many patients were treated in October 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibingo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

### **Response**

Please note that as per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s involved and cause distress to Families or Friends. The numbers for the period requested are less than 5, so Exemption Section 40(2) of the Freedom of Information Act is

Treatment	Patient Count
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	< 5
Dupilumab (Dupixent)	26
Lebrikizumab (Ebglyss)	0
Omalizumab (Xolair)	0
Tralokinumab (Adtralza)	12
Upadacitinib (Rinvoq)	9

### FOI-112024-0001215

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team The Dudley Group NHS Foundation Trust